Altimmune (NASDAQ:ALT) Shares Gap Down – What’s Next?

Altimmune, Inc. (NASDAQ:ALT) gapped down before the market opened on Wednesday . The stock had previously closed at $6.18, but opened at $5.93. Altimmune shares last traded at $5.6750, with a volume of 4,605,667 shares traded.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ALT shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research note on Monday, October 20th. Citizens Jmp lowered their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Friday, November 7th. Citigroup restated a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Barclays assumed coverage on shares of Altimmune in a research report on Tuesday. They set an “overweight” rating and a $20.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Altimmune presently has an average rating of “Moderate Buy” and an average price target of $17.17.

Altimmune Trading Down 11.5%

The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $570.95 million, a price-to-earnings ratio of -5.16 and a beta of 0.04. The business’s 50 day moving average price is $4.63 and its two-hundred day moving average price is $4.13.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%.The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. On average, equities analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In other Altimmune news, Director Jerome Benedict Durso acquired 12,500 shares of Altimmune stock in a transaction that occurred on Monday, December 22nd. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the purchase, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Gill bought 12,500 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was acquired at an average price of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the purchase, the director directly owned 12,500 shares in the company, valued at approximately $51,250. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 30,527 shares of company stock worth $125,278. Corporate insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Kingswood Wealth Advisors LLC increased its holdings in Altimmune by 133.8% in the 4th quarter. Kingswood Wealth Advisors LLC now owns 36,000 shares of the company’s stock worth $130,000 after buying an additional 20,600 shares in the last quarter. Summit Financial Wealth Advisors LLC lifted its position in shares of Altimmune by 7.3% in the fourth quarter. Summit Financial Wealth Advisors LLC now owns 103,288 shares of the company’s stock valued at $373,000 after acquiring an additional 7,000 shares in the last quarter. Wealth Effects LLC boosted its holdings in shares of Altimmune by 86.7% during the 4th quarter. Wealth Effects LLC now owns 111,750 shares of the company’s stock valued at $403,000 after purchasing an additional 51,900 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in shares of Altimmune by 15.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 214,632 shares of the company’s stock valued at $775,000 after purchasing an additional 29,057 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in Altimmune during the 3rd quarter valued at $60,000. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.